Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 4
2009 6
2010 2
2011 9
2012 9
2013 12
2014 15
2015 17
2016 16
2017 12
2018 17
2019 17
2020 23
2021 25
2022 20
2023 16
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Results by year

Filters applied: . Clear all
Page 1
Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
Singh S, Abu-Zaid A, Jin H, Fang J, Wu Q, Wang T, Feng H, Quarni W, Shao Y, Maxham L, Abdolvahabi A, Yun MK, Vaithiyalingam S, Tan H, Bowling J, Honnell V, Young B, Guo Y, Bajpai R, Pruett-Miller SM, Grosveld GC, Hatley M, Xu B, Fan Y, Wu G, Chen EY, Chen T, Lewis PW, Rankovic Z, Li Y, Murphy AJ, Easton J, Peng J, Chen X, Wang R, White SW, Davidoff AM, Yang J. Singh S, et al. Sci Transl Med. 2022 Jul 13;14(653):eabq2096. doi: 10.1126/scitranslmed.abq2096. Epub 2022 Jul 13. Sci Transl Med. 2022. PMID: 35857643 Free PMC article.
Here, we show that the histone lysine demethylase 4B (KDM4B) is a therapeutic vulnerability for PAX3-FOXO1(+) RMS. Genetic and pharmacologic inhibition of KDM4B substantially delayed tumor growth. Suppression of KDM4 proteins inhibited the expression of core oncogen …
Here, we show that the histone lysine demethylase 4B (KDM4B) is a therapeutic vulnerability for PAX3-FOXO1(+) RMS. Genetic and …
PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets.
Zhang S, Wang J, Liu Q, McDonald WH, Bomber ML, Layden HM, Ellis J, Borinstein SC, Hiebert SW, Stengel KR. Zhang S, et al. Mol Cell. 2022 Dec 1;82(23):4428-4442.e7. doi: 10.1016/j.molcel.2022.10.025. Epub 2022 Nov 16. Mol Cell. 2022. PMID: 36395771 Free PMC article.
PAX3-FOXO1 degradation impaired RNA polymerase pause release and transcription elongation at most regulated gene targets. Moreover, the activity of PAX3-FOXO1 at enhancers controlling this core network was surprisingly selective, affecting single eleme
PAX3-FOXO1 degradation impaired RNA polymerase pause release and transcription elongation at most regulated gene targets. More
Myo-differentiation reporter screen reveals NF-Y as an activator of PAX3-FOXO1 in rhabdomyosarcoma.
Sroka MW, Skopelitis D, Vermunt MW, Preall JB, El Demerdash O, de Almeida LMN, Chang K, Utama R, Gryder B, Caligiuri G, Ren D, Nalbant B, Milazzo JP, Tuveson DA, Dobin A, Hiebert SW, Stengel KR, Mantovani R, Khan J, Kohli RM, Shi J, Blobel GA, Vakoc CR. Sroka MW, et al. Proc Natl Acad Sci U S A. 2023 Sep 5;120(36):e2303859120. doi: 10.1073/pnas.2303859120. Epub 2023 Aug 28. Proc Natl Acad Sci U S A. 2023. PMID: 37639593 Free PMC article.
Recurrent chromosomal rearrangements found in rhabdomyosarcoma (RMS) produce the PAX3-FOXO1 fusion protein, which is an oncogenic driver and a dependency in this disease. ...While the transcriptomes of NF-Y- and PAX3-FOXO1-deficient RMS cells bear rema …
Recurrent chromosomal rearrangements found in rhabdomyosarcoma (RMS) produce the PAX3-FOXO1 fusion protein, which is an oncoge …
PAX3-FOXO1: Zooming in on an "undruggable" target.
Wachtel M, Schäfer BW. Wachtel M, et al. Semin Cancer Biol. 2018 Jun;50:115-123. doi: 10.1016/j.semcancer.2017.11.006. Epub 2017 Nov 14. Semin Cancer Biol. 2018. PMID: 29146205 Free article. Review.
One specific example for such a cancer type is alveolar rhabdomyosarcoma, which is associated in the majority of cases with the fusion protein PAX3-FOXO1. Since fusion transcription factors are challenging targets for development of small molecule inhibitors, indire …
One specific example for such a cancer type is alveolar rhabdomyosarcoma, which is associated in the majority of cases with the fusion prote …
Evidence of pioneer factor activity of an oncogenic fusion transcription factor.
Sunkel BD, Wang M, LaHaye S, Kelly BJ, Fitch JR, Barr FG, White P, Stanton BZ. Sunkel BD, et al. iScience. 2021 Jul 16;24(8):102867. doi: 10.1016/j.isci.2021.102867. eCollection 2021 Aug 20. iScience. 2021. PMID: 34386729 Free PMC article.
This study defines the cellular and chromatin localization of PAX3-FOXO1, an oncogenic driver of childhood rhabdomyosarcoma (RMS), derived from a fusion of PFs. ...Our quantitative localization studies address structural variation in RMS genomes and reveal insights …
This study defines the cellular and chromatin localization of PAX3-FOXO1, an oncogenic driver of childhood rhabdomyosarcoma (R …
PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
Linardic CM. Linardic CM. Cancer Lett. 2008 Oct 18;270(1):10-8. doi: 10.1016/j.canlet.2008.03.035. Epub 2008 May 23. Cancer Lett. 2008. PMID: 18457914 Free PMC article. Review.
Of the two, aRMS is associated with an more aggressive disease pattern and a higher mortality, mandating a better understanding of this cancer at the molecular level. The PAX3-FOXO1 fusion gene, resulting from the stable reciprocal translocation of chromosomes 2 and …
Of the two, aRMS is associated with an more aggressive disease pattern and a higher mortality, mandating a better understanding of this canc …
PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
Searcy MB, Larsen RK 4th, Stevens BT, Zhang Y, Jin H, Drummond CJ, Langdon CG, Gadek KE, Vuong K, Reed KB, Garcia MR, Xu B, Kimbrough DW, Adkins GE, Djekidel N, Porter SN, Schreiner PA, Pruett-Miller SM, Abraham BJ, Rehg JE, Hatley ME. Searcy MB, et al. Nat Commun. 2023 Nov 15;14(1):7291. doi: 10.1038/s41467-023-43044-1. Nat Commun. 2023. PMID: 37968277 Free PMC article.
Fusion-positive rhabdomyosarcoma (FP-RMS) driven by the expression of the PAX3-FOXO1 (P3F) fusion oncoprotein is an aggressive subtype of pediatric rhabdomyosarcoma. ...
Fusion-positive rhabdomyosarcoma (FP-RMS) driven by the expression of the PAX3-FOXO1 (P3F) fusion oncoprotein is an aggressive …
Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs.
Manceau L, Richard Albert J, Lollini PL, Greenberg MVC, Gilardi-Hebenstreit P, Ribes V. Manceau L, et al. PLoS Genet. 2022 May 23;18(5):e1009782. doi: 10.1371/journal.pgen.1009782. eCollection 2022 May. PLoS Genet. 2022. PMID: 35604932 Free PMC article.
In addition, PAX7-FOXO1 binding results in greater recruitment of the H3K27ac activation mark than PAX3-FOXO1 binding and is accompanied by greater transcriptional activation of neighbouring genes. ...Altogether, our results argue that the diversity of rhabdomyosarc …
In addition, PAX7-FOXO1 binding results in greater recruitment of the H3K27ac activation mark than PAX3-FOXO1 binding and is a …
PAX3-FOXO1 escapes miR-495 regulation during muscle differentiation.
Xie Z, Tang Y, Su X, Cao J, Zhang Y, Li H. Xie Z, et al. RNA Biol. 2019 Jan;16(1):144-153. doi: 10.1080/15476286.2018.1564464. Epub 2019 Jan 11. RNA Biol. 2019. PMID: 30593263 Free PMC article.
Pax3 plays an essential role in myogenesis. Previously, we found a tumor-signature chimeric fusion RNA, PAX3-FOXO1 also present during muscle differentiation, raising the possibility of its physiological role. ...Examining several other fusion RNAs revealed that the …
Pax3 plays an essential role in myogenesis. Previously, we found a tumor-signature chimeric fusion RNA, PAX3-FOXO1 also presen …
Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.
Nguyen TH, Barr FG. Nguyen TH, et al. Molecules. 2018 Oct 28;23(11):2798. doi: 10.3390/molecules23112798. Molecules. 2018. PMID: 30373318 Free PMC article. Review.
A specific chromosomal translocation t(2;13)(q35;q14) that gives rise to the chimeric oncogenic transcription factor PAX3-FOXO1 has been identified as a hallmark of the aggressive alveolar subtype of RMS. PAX3-FOXO1 cooperates with additional molecular …
A specific chromosomal translocation t(2;13)(q35;q14) that gives rise to the chimeric oncogenic transcription factor PAX3-FOXO1
198 results